The members of the VBU Association of German Biotech Companies (www.v-b-u.org) have unanimously elected Uwe Gottschalk, VP of purification technologies at Sartorius Biotech GmbH (Goettingen, Germany, www.sartorius.com), to the board.
The members of the VBU Association of German Biotech Companies (www.v-b-u.org) have unanimously elected Uwe Gottschalk, VP of purification technologies at Sartorius Biotech GmbH (Goettingen, Germany, www.sartorius.com), to the board. As a result, Gottschalk belongs to the five-member board effective immediately. Gottschalk is also an eminent member of BioPharm International magazine’s editorial advisory board.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.